This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Chemed Rides on VITAS Recovery, Robust Roto-Rooter Sales
by Zacks Equity Research
Chemed (CHE) steers growth with VITAs business' revival from struggle and Roto-Rooter's consistent rise on the back of core plumbing and drain cleaning service segments.
Inogen (INGN) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Inogen (INGN) develops, manufactures and markets POCs. The company's direct-to-customer business model lent it a leading position in the oxygen therapy space.
Cooper to Benefit From Specialty Lenses Prospects Amid Woes
by Zacks Equity Research
The Cooper Companies' (COO) strong sales growth will continue to be aided by a leading position in the market of specialty lenses.
Forget Abbott, Buy These 4 High-Growth MedTech Stocks Instead
by Zacks Equity Research
The share price performance of Abbott Laboratories (ABT) has been disappointing over the last three years. Of the prime issues plaguing Abbott, foreign exchange is a major one.
Align Technology at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Align Technology's (ALGN) efforts to expand worldwide instil confidence in investors. The market is upbeat about the non-exclusive distribution agreement with Patterson Dental.
Buy These 5 Large Caps on Extraordinary ROI Potential
by Zacks Equity Research
Amid heightening tensions in the Korean Peninsula and hurricanes back home, let's take the safer route and invest for the long haul, using ROI as a barometer.
Boston Scientific Grows on Innovation, Buyouts Amid Woes
by Zacks Equity Research
While unfavorable foreign exchange continues to raise concerns, Boston Scientific (BSX) stands steadily on growth track with Symetis acquisition and FDA-approved products.
HealthEquity (HQY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered favorable results in the second quarter of fiscal 2018 on the back of revenue and margin expansion.
Allscripts' (MDRX) dbMotion Platform Selected by SWSPHN
by Zacks Equity Research
The latest development is a significant addition to Allscripts' (MDRX) dbMotion Solution platform customer base. The company is poised to benefit from opportunities in the Asia-Pacific market.
Henry Schein Joins IMF & LUGFA on Prostate Cancer Awareness
by Zacks Equity Research
Henry Schein (HSIC) joins forces with IMF and LUGPA to generate awareness among physicians and people about the importance of early detection of prostate cancer.
Quest Diagnostics (DGX) Banks on Buyouts, Competition Rife
by Zacks Equity Research
Quest Diagnostics (DGX) witnesses significant growth through infectious disease testing, prescription drug monitoring and wellness business.
Medtronic (MDT) & Mazor Robotics Tie-Up Reaches Next Level
by Zacks Equity Research
With an investment of $40 million as a third installment in Mazor Robotics, Medtronic (MDT) will become the exclusive worldwide distributor of the Mazor X system.
Hologic (HOLX) Launches Brevera, Progresses in Breast Health
by Zacks Equity Research
Hologic's (HOLX) Brevera real-time breast biopsy and verification system holds great potential to enhance workflow and patient experience.
4 Large-Cap Medical Device Stocks to Buy Amid Political Woes
by Zacks Equity Research
Investors facing political doldrums can safely place their bets on the Medical Device space on four large-cap medical device stocks that are poised for impressive returns over the next five years.
Mazor Robotics Hits 52-Week High Through Medtronic Alliance
by Zacks Equity Research
Mazor Robotics (MZOR) touched a new 52-week high on the back of favorable amendment of its strategic partnership with Medtronic.
GNC Holdings Gains on New GNC Strength Amid Soft Revenues
by Zacks Equity Research
GNC Holdings (GNC) continues to bank on new GNC plan and global revenues despite lacklustre revenue figures in second quarter of 2017.
3 MedTech Stocks Set to Rally in the Second Half
by Zacks Equity Research
The wide gamut of Medical Device presents interesting choice for investors to profit from rally in the second half of 2017.
Haemonetics Grows on Strong Plasma, Blood Center Sluggish
by Zacks Equity Research
Haemonetics' (HAE) encouraging growth in both Plasma and Haemonetics Management franchises keeps the market upbeat. However, slow revenue growth at the Blood Center franchise raises concern.
Abbott's (ABT) FreeStyle Libre Gets Japan Reimbursement Nod
by Zacks Equity Research
Abbott's (ABT) diabetes care segment to further strengthen with the FreeStyle Libre glucose monitoring system's latest Japanese national reimbursement grant.
The Cooper Companies (COO) Beats Earnings Estimates in Q3
by Zacks Equity Research
The Cooper Companies (COO) provided strong guidance for fiscal 2017. However, the soft outlook for CooperSurgical indicates looming concerns.
Amedisys to Buy Intercity Home Care, Boosts Personal Care Arm
by Zacks Equity Research
Amedisys (AMED) to strengthen its position in Personal Care business in Massachusetts with this recently signed acquisition deal.
Abbott's AMPLATZER Pivotal Study to Strengthen Vascular Arm
by Zacks Equity Research
Abbott (ABT) is consistently trying to expand its vascular business. It has initiated the clinical study of AMPLATZER device to correct common congenital heart defect in newborns.
BioScrip's Infusion Business Strong, Dull 2017 View a Drag (Revised)
by Zacks Equity Research
BioScrip's (BIOS) progressive CORE plan should enhance its financial position. However, the company's 2017 outlook loses steam based on an anticipated adverse impact of Cures Act legislation.
Phibro Animal (PAHC) Beats Q4 Earnings & Sales Estimates
by Zacks Equity Research
Phibro Animal (PAHC) reported solid fourth-quarter fiscal 2017 revenues on the back of sales growth in the Animal Health, Mineral Nutrition and Performance Products segments.
VWR Awaits Merger Closure, Stock Upside Potential Limited
by Zacks Equity Research
VWR Corporation's (VWR) $6.4 billion acquisition by Avantor should create a major consumables-focused solutions and services provider to lucrative life sciences and advanced technologies industries.